文献速递消化道肿瘤放疗放疗物理与技术

FGF1/CPP-C嵌合蛋白可减轻碳离子放疗的肠道不良反应而不加剧胰腺癌

The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-10-24

本研究在BALB/c小鼠中经腹腔给予FGF1/CPP-C(无肝素),于低线性能量传输碳离子(17 keV/μm)6-8 Gy全身照射前12小时给药,评估空肠放射性保护作用;并以MIAPaCa-2和PANC-1人胰腺癌细胞系评估侵袭与迁移。结果显示FGF1/CPP-C在7-8 Gy照射后促进隐窝存活、抑制凋亡并减少γH2AX焦点,且对胰腺癌细胞增殖、侵袭和迁移的抑制作用强于FGF1,提示其在不加剧胰腺癌恶性程度的前提下减轻碳离子放疗肠道不良反应。

要点

  • FGF1/CPP-C在碳离子7-8 Gy照射后促进隐窝存活显著优于FGF1。
  • FGF1/CPP-C抑制碳离子放疗诱导的凋亡并减少隐窝细胞γH2AX焦点,作用强于FGF1。
  • FGF1/CPP-C对MIAPaCa-2和PANC-1细胞的增殖、侵袭和迁移抑制作用显著强于FGF1。

核心结论

  • FGF1/CPP-C的细胞内信号模式可减轻碳离子放疗的肠道不良反应,且不加剧胰腺癌的恶性程度。

研究设计与样本

  • 动物实验:FGF1/CPP-C在不含肝素条件下经腹腔给予BALB/c小鼠,于低线性能量传输碳离子(17 keV/μm)6-8 Gy全身照射前12小时给药,评估空肠放射性保护作用。
  • 体外实验:人胰腺癌细胞系MIAPaCa-2和PANC-1经FGF1/CPP-C培养后用Boyden小室评估侵袭和迁移。

主要发现

  • FGF1/CPP-C在碳离子7-8 Gy照射后促进隐窝存活显著多于FGF1处理。
  • FGF1/CPP-C抑制碳离子放疗诱导的凋亡并减少隐窝细胞γH2AX焦点,作用多于FGF1。
  • FGF1/CPP-C抑制FGFR下游信号通路并抑制肠道细胞周期调控分子活化直至全身照射后4小时。
  • IEC6细胞经FGF1/CPP-C或FGF1培养后阻滞于G2M期,提示FGF1/CPP-C诱导的G2M阻滞促进照射后DNA修复。
  • FGF1/CPP-C被MIAPaCa-2和PANC-1细胞内化的效率高于FGF1,并显著更多抑制两种细胞的体外增殖、侵袭和迁移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Carbon ion (C-ion) beams are concentrated to irradiate pancreatic carcinoma in the upper abdomen; however, this radiotherapy potentially causes adverse reactions in the gastrointestinal tract. FGF1 is a candidate radioprotector for radiation-induced intestinal damage, but may promote the malignancy of pancreatic cancer. An FGF1/CPP-C chimeric protein was created to enhance the intracellular signaling mode of FGF1 instead of FGFR signaling. The present study investigated the effects of FGF1/CPP-C on the intestinal adverse reactions of C-ion radiotherapy as well as its influence on the malignancy of pancreatic cancer. MATERIALS AND METHODS: FGF1/CPP-C was administered intraperitoneally to BALB/c mice without heparin 12 h before total body irradiation (TBI) with low-LET C-ion (17 keV/μm) at 6-8 Gy. Several radioprotective effects were examined in the jejunum. The invasion and migration of the human pancreatic carcinoma cell lines MIAPaCa-2 and PANC-1 were assessed using Boyden chambers after cultures with FGF1/CPP-C. RESULTS: The FGF1/CPP-C treatment promoted crypt survival after C-ion irradiation at 7-8 Gy significantly more than the FGF1 treatment. FGF1/CPP-C also inhibited C-ion radiotherapy-induced apoptosis and reduced γH2AX foci in crypt cells more than FGF1. However, FGF1/CPP-C inhibited the downstream signaling pathways of FGFRs and suppressed the activation of cell-cycle regulatory molecules in the intestine until 4 h after TBI. Furthermore, IEC6 cells were arrested in G2M after cultures with FGF1/CPP-C or FGF1, suggesting that DNA repair after irradiation is promoted by FGF1/CPP-C-induced G2M arrest. In contrast, FGF1/CPP-C appeared to be internalized into MIAPaCa-2 and PANC-1 cells more efficiently than FGF1. Therefore, FGF1/CPP-C reduced the in vitro proliferation, invasion, and migration of MIAPaCa-2 and PANC-1 cells significantly more than FGF1 through the cellular internalization of FGF1. CONCLUSION: These results suggest that the intracellular signaling mode of FGF1/CPP-C attenuates the intestinal adverse effects of C-ion radiotherapy without enhancing the malignancy of pancreatic carcinoma.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kawano M, Miura T, Fujita M, et al. The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma. Clin Transl Radiat Oncol. 2018. PMID: 30406211. doi:10.1016/j.ctro.2018.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。